Science Explorer Back to mapMap
Discussion
Company · Vernier · Switzerland

Eli Lilly (Switzerland)

lilly.chROR OpenAlex
Research works
16
▲ 44% vs 2018-21
Citations
149
9.6 per fractional work
Top-10% rate
7.0%
all institutions 10.0%
Open access
51%
world 40%
International
63%
world 18%
Eli Lilly (Switzerland)

Not ranked overall: Eli Lilly (Switzerland) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Eli Lilly (Switzerland) work in?

In all years, 66% of research at Eli Lilly (Switzerland) is in Health Sciences, 24% in Life Sciences. Its largest fields are Medicine (58%), Biochemistry, Genetics and Molecular Biology (9%), Health Professions (7%). It does 2.0× the world's share of Health Sciences.

Health Sciences: 10 fractional works · 65.9% of its workMedicine: 9 fractional works · 58.4% of its workRheumatology: 1 fractional works · 8.9% of its workEndocrinology, Diabetes and Metabolism: 1 fractional works · 7.2% of its workRadiology, Nuclear Medicine and Imaging: 1 fractional works · 5.8% of its workOncology: 1 fractional works · 5.1% of its workPublic Health, Environmental and Occupational Health: 1 fractional works · 4.4% of its workPharmacology: 1 fractional works · 3.9% of its workPulmonary and Respiratory Medicine: 1 fractional works · 3.6% of its workEpidemiology: 1 fractional works · 3.5% of its workCardiology and Cardiovascular Medicine: 0 fractional works · 2.3% of its workInfectious Diseases: 0 fractional works · 2.3% of its workPhysiology: 0 fractional works · 2.1% of its workFamily Practice: 0 fractional works · 1.7% of its workSurgery: 0 fractional works · 1.7% of its workGenetics: 0 fractional works · 1.5% of its workPsychiatry and Mental health: 0 fractional works · 1.3% of its workPathology and Forensic Medicine: 0 fractional works · 0.8% of its workGeriatrics and Gerontology: 0 fractional works · 0.6% of its workHealth Informatics: 0 fractional works · 0.6% of its workGastroenterology: 0 fractional works · 0.4% of its workPediatrics, Perinatology and Child Health: 0 fractional works · 0.4% of its workHematology: 0 fractional works · 0.3% of its workHealth Professions: 1 fractional works · 6.7% of its workGeneral Health Professions: 1 fractional works · 4.3% of its workPharmacy: 0 fractional works · 2.4% of its workVeterinary: 0 fractional works · 0.7% of its workSmall Animals: 0 fractional works · 0.7% of its workLife Sciences: 4 fractional works · 24.2% of its workBiochemistry, Genetics and Molecular Biology: 1 fractional works · 9.3% of its workMolecular Biology: 1 fractional works · 4.5% of its workGenetics: 0 fractional works · 2.8% of its workMolecular Medicine: 0 fractional works · 1.1% of its workCancer Research: 0 fractional works · 1.0% of its workImmunology and Microbiology: 1 fractional works · 5.8% of its workImmunology: 1 fractional works · 4.8% of its workApplied Microbiology and Biotechnology: 0 fractional works · 1.1% of its workNeuroscience: 1 fractional works · 4.6% of its workCellular and Molecular Neuroscience: 0 fractional works · 2.4% of its workBiological Psychiatry: 0 fractional works · 2.1% of its workPharmacology, Toxicology and Pharmaceutics: 1 fractional works · 4.4% of its workPharmacology: 1 fractional works · 4.4% of its workAgricultural and Biological Sciences: 0 fractional works · 0.2% of its workSocial Sciences: 1 fractional works · 5.8% of its workEconomics, Econometrics and Finance: 1 fractional works · 3.7% of its workEconomics and Econometrics: 1 fractional works · 3.7% of its workDecision Sciences: 0 fractional works · 2.1% of its workStatistics, Probability and Uncertainty: 0 fractional works · 2.1% of its workPhysical Sciences: 1 fractional works · 4.0% of its workMathematics: 0 fractional works · 2.1% of its workStatistics and Probability: 0 fractional works · 2.1% of its workComputer Science: 0 fractional works · 0.6% of its workArtificial Intelligence: 0 fractional works · 0.4% of its workSmaller subfields together: 0 fractional works · 0.2% of its workEarth and Planetary Sciences: 0 fractional works · 0.5% of its workAtmospheric Science: 0 fractional works · 0.5% of its workEnvironmental Science: 0 fractional works · 0.5% of its workHealth, Toxicology and Mutagenesis: 0 fractional works · 0.5% of its workEngineering: 0 fractional works · 0.3% of its workBiomedical Engineering: 0 fractional works · 0.3% of its workALL ITS WORKEli Lilly(Switzerland)16fractional works, all years
Life Sciences24%Physical Sciences4%Health Sciences66%Social Sciences6%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 15 fields, with their numbers
    1. Medicine958.4%
    2. Health Professions16.7%
    3. Veterinary00.7%
    1. Biochemistry, Genetics and Molecular Biology19.3%
    2. Immunology and Microbiology15.8%
    3. Neuroscience14.6%
    4. Pharmacology, Toxicology and Pharmaceutics14.4%
    5. Agricultural and Biological Sciences00.2%
    1. Economics, Econometrics and Finance13.7%
    2. Decision Sciences02.1%
    1. Mathematics02.1%
    2. Computer Science00.6%
    3. Earth and Planetary Sciences00.5%
    4. Environmental Science00.5%
    5. Engineering00.3%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Biochemistry, Genetics and Molecular Biology: 2.31× its world share, 1 worksBiochemistry, Geneti…Immunology and Microbiology: 7.82× its world share, 0 worksImmunology and Micro…Neuroscience: 0.56× its world share, 0 worksNeuroscienceComputer Science: 0.24× its world share, 0 worksComputer ScienceMathematics: 5.39× its world share, 0 worksMathematicsHealth Professions: 0.34× its world share, 0 worksHealth ProfessionsMedicine: 3.44× its world share, 4 worksMedicineEconomics, Econometrics and Finance: 1.71× its world share, 0 worksEconomics, Econometr…1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 7.8×. Every wedge is a field page.

All 8 fields, with their numbers
  1. Immunology and Microbiology7.82×0 works
  2. Mathematics5.39×0 works
  3. Medicine3.44×4 works
  4. Biochemistry, Genetics and Molecular Biology2.31×1 works
  5. Economics, Econometrics and Finance1.71×0 works
  6. Neuroscience0.56×0 works
  7. Health Professions0.34×0 works
  8. Computer Science0.24×0 works

What are the most cited papers from Eli Lilly (Switzerland)?

The most cited paper from Eli Lilly (Switzerland) is "European registry on patients with ST-elevation myocardial infarction transferred for mechanical reperfusion with a special focus on early administration of abciximab—EUROTRANSFER Registry" (Dariusz Dudek, Zbigniew Siudak, Magnus Janzon et al., 2008), with 70 citations. Next come "Early versus periprocedural administration of abciximab for primary angioplasty: A pooled analysis of 6 studies" (58) and "A Class Comparison of Medication Persistence in People with Type 2 Diabetes: A Retrospective Observational Study" (48).

Most cited papers
#PaperReleasedCitations
1 European registry on patients with ST-elevation myocardial infarction transferred for mechanical reperfusion with a special focus on early administration of abciximab—EUROTRANSFER Registry Dariusz Dudek, Zbigniew Siudak, Magnus Janzon et al. · American Heart Journal 20 Oct 2008 70
2 Early versus periprocedural administration of abciximab for primary angioplasty: A pooled analysis of 6 studies Jochen Gödicke, Marcus D Flather, Marko Noč et al. · American Heart Journal Nov 2005 58
3 A Class Comparison of Medication Persistence in People with Type 2 Diabetes: A Retrospective Observational Study Andrew McGovern, William Hinton, Silvio Calderara et al. · Diabetes Therapy Open access 4 Jan 2018 48
4 Declining Enrolment and Other Challenges in IBD Clinical Trials: Causes and Potential Solutions Mathieu Uzzan, Yoram Bouhnik, María T. Abreu et al. · Journal of Crohn s and Colitis 2 Feb 2023 38
5 The impact of disease severity and duration on cost, early retirement and ability to work in rheumatoid arthritis in Europe: an economic modelling study James Benjamin Galloway, Jean-Philippe Capron, Francesco De Leonardis et al. · Rheumatology Advances in Practice Open access 2020 36
All 45 most cited papers, with filters and sorting

Which research topics does Eli Lilly (Switzerland) publish most on?

By volume in 2022-now: Medical Imaging Techniques and Applications, Rheumatoid Arthritis Research and Therapies, Inflammatory Bowel Disease and Tuberculosis Research and Epidemiology.

Medical Imaging Techniqu…1Medical Imaging Techniques and Applications: 1 fractional worksRheumatoid Arthritis Res…0Rheumatoid Arthritis Research and Therapies: 0 fractional worksInflammatory Bowel Disease0Inflammatory Bowel Disease: 0 fractional worksTuberculosis Research and Epidemiology: 0 fractional worksBiosimilars and Bioanalytical Methods: 0 fractional worksStatistical Methods in C…0Statistical Methods in Clinical Trials: 0 fractional worksBiological Research and Disease Studies: 0 fractional worksHealth Systems, Economic Evaluations, Quality of Life: 0 fractional worksAdvanced Causal Inference Techniques: 0 fractional worksCytokine Signaling Pathways and Interactions: 0 fractional works
Radiology, Nuclear Medicine and ImagingRheumatologyGeneticsInfectious Diseases5 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Medical Imaging Techniques and Applications Radiology, Nuclear Medicine and Imaging 1 works
  2. 2 Rheumatoid Arthritis Research and Therapies Rheumatology 0 works
  3. 3 Inflammatory Bowel Disease Genetics 0 works
  4. 4 Tuberculosis Research and Epidemiology Infectious Diseases 0 works
  5. 5 Biosimilars and Bioanalytical Methods Immunology 0 works
  6. 6 Statistical Methods in Clinical Trials Statistics and Probability 0 works
  7. 7 Biological Research and Disease Studies Molecular Biology 0 works
  8. 8 Health Systems, Economic Evaluations, Quality of Life Economics and Econometrics 0 works
  9. 9 Advanced Causal Inference Techniques Statistics and Probability 0 works
  10. 10 Cytokine Signaling Pathways and Interactions Oncology 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available51.2%not open48.8%

World: 40% of research is openly available.

with international co-authors62.6%domestic only37.4%

World: 18% is written across borders.

How has Eli Lilly (Switzerland)'s research output changed?

Output in 2022-2025 was 44% higher than in 2018-2021.

still counting1990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Eli Lilly (Switzerland) as a percentage of every work published that year, 0.000022% in 2024.

still counting0.00010%0.00020%Eli Lilly (Switzerland)0.000014% in 20251990200020102020

Fractional works of Eli Lilly (Switzerland) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Vernier

All research institutions in Vernier

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Eli Lilly (Switzerland). Posts are plain text and can be reported.